Ticker

Hyperion DeFi (NASDAQ: HYPD - Get Free Report) and Neuren Pharmaceuticals (OTCMKTS:NURPF - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk. Valuation and Earnings This table compares Hyperion DeFi

Hyperion DeFi, Inc. (HYPD) Q4 2025 Earnings Call Transcript

Five Diversified, Ramping DeFi Business Lines Delivered Growth Exceeding Q4 Guidance Treasury Exceeds 1.93M HYPE, 1.92M KNTQ, & 1.00M HPL Tokens as of March 23 (14) HYPD's Unique “Triple-Dip” HYPE Deployment Generated ~3x Base Staking Income in Q4 Announces Executed LOI to Monetize the Optejet, With Potential Closing in Q2'26 LAGUNA HILLS, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD)…

Shares of Hyperion DeFi, Inc. (NASDAQ: HYPD - Get Free Report) have earned an average rating of "Hold" from the five ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to

Unlocks Cost-Optimized On-Chain Credit Access, Additional Ecosystem Rewards, and Expanded Revenue Opportunities in Institutional Credit Unlocks Cost-Optimized On-Chain Credit Access, Additional Ecosystem Rewards, and Expanded Revenue Opportunities in Institutional Credit